RhumbLine Advisers
RNAC icon

RhumbLine Advisers’s Cartesian Therapeutics RNAC Stock Holding History

RhumbLine Advisers’s Portfolio RNAC Stock Details RNAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$109K Buy
15,164
+1,671
+12% +$14.5K ﹤0.01% 3489
2026
Q2 		$141K Buy
13,493
+1,133
+9% +$8.39K ﹤0.01% 3413
2026
Q1 		$76K Buy
12,360
+221
+2% +$1.57K ﹤0.01% 3505
2025
Q4 		$87.5K Sell
12,139
-995
-8% -$8.04K ﹤0.01% 3519
2025
Q3 		$134K Sell
13,134
-37
-0.3% -$416 ﹤0.01% 3400
2025
Q2 		$137K Buy
13,171
+165
+1% +$1.76K ﹤0.01% 3422
2025
Q1 		$171K Buy
13,006
+2,805
+27% +$50.1K ﹤0.01% 3185
2024
Q4 		$183K Buy
10,201
+927
+10% +$18.8K ﹤0.01% 3240
2024
Q3 		$149K Buy
9,274
+787
+9% +$12.3K ﹤0.01% 3372
2024
Q2 		$229K Buy
8,487
+4,158
+96% +$99.2K ﹤0.01% 3146
2024
Q1 		$84.4K Buy
4,329
+78
+2% +$1.65K ﹤0.01% 3489
2023
Q4 		$87.9K Buy
4,251
+47
+1% +$1.4K ﹤0.01% 3489
2023
Q3 		$134K Buy
4,204
+211
+5% +$7.05K ﹤0.01% 3359
2023
Q2 		$134K Buy
+3,993
New +$143K ﹤0.01% 3416
2022
Q2 		– Sell
-3,618
Closed -$134K – 3213
2022
Q1 		$134K Buy
3,618
+2
+0.1% +$125 ﹤0.01% 2840
2021
Q4 		$354K Buy
3,616
+11
+0.3% +$1.18K ﹤0.01% 2650
2021
Q3 		$450K Buy
3,605
+98
+3% +$11.8K ﹤0.01% 2595
2021
Q2 		$440K Buy
3,507
+1,196
+52% +$142K ﹤0.01% 2619
2021
Q1 		$314K Sell
2,311
-56
-2% -$6.95K ﹤0.01% 2690
2020
Q4 		$215K Buy
2,367
+329
+16% +$28.5K ﹤0.01% 2810
2020
Q3 		$152K Sell
2,038
-440
-18% -$33.7K ﹤0.01% 2768
2020
Q2 		$211K Buy
+2,478
New +$225K ﹤0.01% 2745
2019
Q2 		– Sell
-1,139
Closed -$81K – 3002
2019
Q1 		$81K Buy
1,139
+346
+44% +$21.9K ﹤0.01% 2885
2018
Q4 		$63K Buy
793
+265
+50% +$60.5K ﹤0.01% 2924
2018
Q3 		$246K Sell
528
-32
-6% -$12.9K ﹤0.01% 2621
2018
Q2 		$222K Buy
560
+170
+44% +$60.3K ﹤0.01% 2686
2018
Q1 		$119K Buy
390
+35
+10% +$10K ﹤0.01% 2715
2017
Q4 		$105K Sell
355
-59
-14% -$25.8K ﹤0.01% 2767
2017
Q3 		$227K Buy
414
+12
+3% +$6.38K ﹤0.01% 2673
2017
Q2 		$239K Buy
+402
New +$178K ﹤0.01% 2670

Other funds holding RNAC

Squarepoint
Squarepoint New York $90.8B AUM 26.98% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Privium Fund Management
Privium Fund Management Amsterdam, Netherlands $516M AUM 18.66% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $85.7B AUM 51.02% 1-Year Est. Return
Fedenia Advisers
Fedenia Advisers Madison, Wisconsin $425M AUM 89.76% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Miller Financial Services
Miller Financial Services Marshall, Michigan $132M AUM 10.64% 1-Year Est. Return

RhumbLine Advisers's RNAC Position: Q3 2026 in Review

RhumbLine Advisers increased its Cartesian Therapeutics (RNAC) stake by 12% in Q3 2026, buying an estimated $14.5K and bringing the position to 15,164 shares worth $109K. The position accounts for ﹤0.01% of the portfolio, ranked #3489.

RhumbLine Advisers first reported a position in RNAC in Q2 2017 and has held it in 30 quarters since. The position peaked at $450K in Q3 2021. 42 funds tracked by Wall St. Rank hold RNAC as of Q3 2026.

  • RhumbLine Advisers held 15,164 shares of Cartesian Therapeutics worth $109K as of Q3 2026.
  • RhumbLine Advisers bought 1,671 Cartesian Therapeutics shares in Q3 2026, an estimated $14.5K.
  • Cartesian Therapeutics made up ﹤0.01% of RhumbLine Advisers's portfolio in Q3 2026, its #3489 holding.
  • RhumbLine Advisers first reported a position in Cartesian Therapeutics in Q2 2017 and has held it in 30 quarters since.
  • RhumbLine Advisers's Cartesian Therapeutics position peaked at $450K in Q3 2021.
  • 42 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q3 2026.

Based on RhumbLine Advisers's 13F filing for Q3 2026, filed 10 Nov 2026.